ferric citrate has been researched along with Kidney Failure, Chronic in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 20 (83.33) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Aslam, N; Basdeo, LM; Govani, M; Wadei, HM | 1 |
| Rascati, K | 1 |
| Block, GA; Chertow, GM; Fishbane, S; Neylan, JF; Pergola, PE; Uhlig, K | 1 |
| Block, GA; Block, MS; Chertow, GM; Isakova, T; Mehta, R; Smits, G; Wolf, M | 1 |
| Akiba, T; Chertow, GM; Fukagawa, M; Hirakata, H; Kumagai, Y; Nakayama, M; Sawada, K; Yokoyama, K | 1 |
| Chiang, SS; Lee, CT; Peng, YS; Shu, KH; Wu, IW; Wu, MJ; Wu, MS | 1 |
| Athreya, BP; Blumenthal, SS; Chang, IJ; Chuang, P; Dwyer, JP; Galphin, CM; Greene, T; Kant, KS; Koury, MJ; Lewis, JB; Linfert, DR; Manley, J; Nossuli, AK; Olivero, JJ; Schulman, G; Sika, M; Smith, MT; Whittier, FC; Zeig, S | 1 |
| Dwyer, JP; Niecestro, R; Rodby, R; Sinsakul, M; Umanath, K | 1 |
| Thompson, CA | 1 |
| Dwyer, JP; Jackson, JH; Lewis, JB; Niecestro, R; Rodby, R; Sika, M; Umanath, K | 1 |
| Blumenthal, SS; Dwyer, JP; Greco, BA; Greene, T; Hiremath, AN; Jalal, DI; Koury, MJ; Lewis, JB; Ma, KN; Manley, J; Negoi, DG; Niecestro, R; Reisin, E; Sika, M; Umanath, K; Umeukeje, EM; Zeig, S | 1 |
| Abraham, JD; Arfeen, SS; Bowline, IG; Chernin, G; Dwyer, JP; Fadem, SZ; Goral, S; Greene, T; Koury, M; Lewis, JB; Middleton, J; Sika, M; Sinsakul, MV; Umanath, K; Van Buren, PN; Weiner, DE | 1 |
| Bond, TC; Dwyer, JP; Lewis, J; Niecestro, R; Rodby, RA; Sika, M; Umanath, K | 1 |
| Iguchi, A; Iino, N; Kazama, JJ; Narita, I; Watanabe, Y; Yamamoto, S; Yoshita, K | 1 |
| Fishbane, S; Hazzan, AD; Shah, HH | 1 |
| Vaziri, ND | 1 |
| Block, GA | 1 |
| Aguilar, E; Dwyer, JP; Goral, S; Greco, B; Greene, T; Jalal, D; Lewis, JB; McFadden, M; Sika, M; Umanath, K; Yagil, Y | 1 |
| Connelly, C; Dwyer, JP; Koury, MJ; Lewis, JB; Niecestro, R; Schulman, G; Sika, M; Umanath, K | 1 |
| Dwyer, J; Greene, T; Korbet, S; Koury, M; Lewis, J; Shapiro, W; Sika, M; Sinsakul, M; Smith, M | 1 |
| Anger, M; Blumenthal, SS; Chang, IJ; Dwyer, JP; Kaplan, M; Koury, MJ; Lewis, JB; Schulman, G; Sika, M; Smith, M; Zeig, S | 1 |
| Andrés, E; Ballarín, J; Barceló, P; Bover, J; Ortiz-Herbener, F | 1 |
| Dhar, SK; Magana, L; Martinez, C; Smith, EC | 1 |
| Ghosh, AK | 1 |
5 review(s) available for ferric citrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
Topics: Anemia; Chelating Agents; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Phosphates; Phosphorus | 2014 |
Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis.
Topics: Anemia, Iron-Deficiency; Dialysis Solutions; Diphosphates; Ferric Compounds; Hematinics; Humans; Iron; Kidney Failure, Chronic; Renal Dialysis | 2016 |
Safety Issues in Iron Treatment in CKD.
Topics: Anemia, Iron-Deficiency; Cardiovascular Diseases; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Disease Progression; Ferric Compounds; Hematinics; Humans; Iron Compounds; Iron Overload; Kidney Failure, Chronic; Oxidative Stress; Reactive Oxygen Species; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
Ferric Citrate in Patients With Chronic Kidney Disease.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Hematinics; Humans; Kidney Failure, Chronic; Renal Dialysis; Renal Insufficiency, Chronic | 2016 |
[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Epoxy Compounds; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Multivariate Analysis; Niacinamide; Phosphate-Binding Proteins; Phosphates; Phosphorus; Polyamines; Polyethylenes; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sevelamer; Time Factors | 2005 |
12 trial(s) available for ferric citrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Female; Ferric Compounds; Humans; Kidney Failure, Chronic; Male; Middle Aged; Placebos | 2017 |
A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
Topics: Aged; Anemia, Iron-Deficiency; Female; Ferric Compounds; Ferritins; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Hemoglobins; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Length of Stay; Male; Middle Aged; Patient Admission; Phosphates; Pilot Projects; Renal Dialysis; Transferrin | 2019 |
A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
Topics: Adult; Chelating Agents; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Polyamines; Renal Dialysis; Sevelamer; Young Adult | 2014 |
Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Chelating Agents; Double-Blind Method; Female; Ferric Compounds; Ferritins; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus; Renal Dialysis; Transferrin | 2015 |
Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
Topics: Anemia, Iron-Deficiency; Dose-Response Relationship, Drug; Female; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Israel; Kidney Failure, Chronic; Male; Middle Aged; Outcome Assessment, Health Care; Phosphorus; Renal Dialysis; Treatment Outcome; United States | 2015 |
Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs.
Topics: Adult; Chelating Agents; Cost Savings; Ferric Compounds; Hospital Costs; Hospitalization; Humans; Kidney Failure, Chronic; Phosphorus; Renal Dialysis | 2015 |
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.
Topics: Administration, Intravenous; Anemia; Drug Therapy, Combination; Female; Ferric Compounds; Hematinics; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged | 2015 |
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Topics: Acetates; Aged; Calcium; Calcium Compounds; Chelating Agents; Female; Ferric Compounds; Humans; Hyperphosphatemia; Inflammation Mediators; Kidney Failure, Chronic; Male; Middle Aged; Phosphates; Polyamines; Renal Dialysis; Sevelamer | 2015 |
Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.
Topics: Drug Costs; Female; Ferric Compounds; Hematinics; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2015 |
Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
Topics: Adolescent; Adult; Chelating Agents; Female; Ferric Compounds; Humans; Kidney Failure, Chronic; Male; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2013 |
The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
Topics: Adult; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Color; Constipation; Feces; Female; Ferric Compounds; Ferritins; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus; Renal Dialysis; Surveys and Questionnaires | 2012 |
Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Female; Ferric Compounds; Follow-Up Studies; Hematinics; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Time Factors; Treatment Outcome | 2013 |
7 other study(ies) available for ferric citrate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Can ferric citrate lead to iron overload in peritoneal dialysis patients?
.
Topics: Aged; Female; Ferric Compounds; Humans; Hyperphosphatemia; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis | 2020 |
Comment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode".
Topics: Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Phosphates; Renal Dialysis | 2017 |
Ferric citrate approved as phosphate binder for patients on dialysis.
Topics: Diet; Ferric Compounds; Humans; Kidney Failure, Chronic; Phosphates; Renal Dialysis | 2014 |
Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
Topics: 25-Hydroxyvitamin D 2; Adult; Aged; Anemia, Iron-Deficiency; Bone Diseases; Chelating Agents; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Sevelamer; Young Adult | 2015 |
Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.
Topics: Chelating Agents; Female; Ferric Compounds; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis | 2017 |
Iron absorption and utilization in maintenance hemodialysis patients: oral and intravenous routes.
Topics: Drug Therapy, Combination; Female; Ferric Compounds; Ferrous Compounds; Humans; Intestinal Absorption; Iron; Iron-Dextran Complex; Kidney Failure, Chronic; Male; Renal Dialysis | 1984 |
Efficacy of ferric citrate as a phosphate-binding agent in end-stage renal disease.
Topics: Ferric Compounds; Humans; Kidney Failure, Chronic; Phosphates; Reproducibility of Results; Research Design | 2002 |